The Agnelli-Elkann family holding company Exor has secured permission to raise its stake in Royal Philips to 22%, extending its grip on the Dutch health technology giant it rescued from a crisis three years ago. The revised long-term accord, announced on August 11, 2026, allows Exor to surpass its previous 20% ceiling without requiring immediate board approval—a flexibility that could deepen Italy's most powerful corporate dynasty's influence over a company with more than €18B in annual revenue.
Why This Matters
• Exor can now buy up to 22% of Philips' share capital and voting rights, up from the 20% cap previously in place.
• Governance remains unchanged, meaning Exor keeps its seat on the Philips Supervisory Board without triggering additional scrutiny.
• Philips shares rose 0.63% in pre-market trading following the announcement, reflecting investor confidence in the Italian-backed turnaround strategy.
• Any increase beyond 22% would require explicit approval from Philips' Supervisory Board, preserving some checks on Exor's growing footprint.
Italy's Agnelli Dynasty Doubles Down on Healthcare Bet
Exor, the €30B investment vehicle controlled by John Elkann and the Agnelli family—best known for their ownership of Juventus Football Club, Ferrari, and the publisher of The Economist—has steadily expanded its footprint in Philips since taking a 15% stake in August 2023. At the time, the Amsterdam-based manufacturer was still reeling from a 2021 recall crisis involving millions of defective sleep apnea machines, which had wiped out billions in market value and triggered regulatory investigations across the U.S. and Europe.
By early 2026, Exor had quietly raised its holding to 19%, making it Philips' single largest shareholder. The updated accord effectively grants Exor the freedom to add another 3 percentage points at will, a privilege that reflects both the Italian group's confidence in Philips' recovery trajectory and its desire to lock in exposure to a sector—health technology—that Exor sees as a growth engine for the next decade.
"We support Philips' long-term strategy, defined by innovation, value creation, and disciplined execution," Elkann said in a statement. "This updated agreement reflects our continued commitment as Philips' largest shareholder." The language echoes the rationale Exor gave for its initial investment: a belief that Philips, once a sprawling conglomerate making everything from light bulbs to electric razors, could be transformed into a focused, high-margin player in diagnostic imaging, patient monitoring, and connected care.
What This Means for Investors and the Market
The market greeted the news with cautious optimism. Philips' New York-listed shares (NYSE: PHG) have gained substantially since Exor first became the anchor investor, reflecting growing confidence in the company's recovery trajectory and strategic direction.
For investors with ties to Italy, the development underscores the Agnelli family's evolving strategy: diversifying beyond traditional industrial and luxury assets into healthcare and technology. Exor's portfolio already includes stakes in Stellantis (the automotive group formed by the merger of Fiat Chrysler and PSA), CNH Industrial, and The Economist Group. Adding Philips provides direct exposure to an industry benefiting from aging demographics in Europe and rising demand for home healthcare devices.
The revised cap also signals that Exor intends to remain a minority investor, not a takeover artist. The 22% threshold—and the requirement for board approval beyond that—suggests a partnership model rather than a hostile acquisition path. This aligns with Italian corporate culture, where long-term strategic stakes and patient capital are often preferred over activist tactics.
Governance Stays Intact, but Influence Grows
Despite the increase in potential ownership, the governance framework agreed in 2023 remains untouched. Exor retains the right to nominate one member to Philips' Supervisory Board, a position currently held by an Exor representative who participates in oversight of the company's strategy and risk management. This arrangement gives Exor a formal voice in boardroom discussions without triggering the regulatory and public scrutiny that might accompany a controlling stake or a full takeover bid.
However, the practical influence of holding 22% of a publicly traded company should not be underestimated. In shareholder votes, Exor would command a decisive bloc, particularly in scenarios where retail and institutional investors are fragmented. This leverage could prove valuable if Philips faces strategic crossroads—such as divesting underperforming units, pursuing major acquisitions, or navigating regulatory challenges in key markets like the United States or the European Union.
Philips' 2026-2028 Plan: The Strategic Backdrop
The timing of the updated accord coincides with Philips' unveiling of its 2026-2028 strategic plan, which emphasizes profitable growth, innovation in connected diagnostics, and operational efficiency. CEO Roy Jakobs, who took the helm in 2022 amid the fallout from the recall crisis, has made restoring investor confidence a top priority. Under his leadership, Philips has streamlined operations, divested non-core businesses, and invested heavily in digital health platforms that integrate hospital equipment with cloud-based analytics.
Jakobs welcomed Exor's renewed commitment, stating that the updated agreement "reflects Exor's support for the implementation of our 2026-2028 plan and our commitment to delivering profitable growth." For Philips, having a stable, long-term anchor shareholder like Exor provides a buffer against short-term market volatility and activist pressure—luxuries that can be crucial when executing multi-year turnarounds in capital-intensive sectors.
Why Healthcare Matters for Italy-Based Investors
For Italy-based investors and businesses, the Exor-Philips relationship offers a window into how Italian capital is being deployed globally in high-growth sectors. While Italy's domestic economy remains anchored by small and medium-sized enterprises (SMEs) in manufacturing, fashion, and agriculture, the country's wealthiest families are increasingly looking abroad for diversification and scale.
Healthcare technology represents a particularly attractive target. Europe's aging population—Italy has one of the highest median ages in the world—is driving demand for home monitoring devices, telemedicine platforms, and diagnostic tools that can reduce hospital admissions and manage chronic conditions remotely. Philips' product lines, which include everything from MRI machines to connected toothbrushes, are well-positioned to benefit from these demographic tailwinds.
Moreover, the investment underscores a broader shift in Italian corporate strategy: moving up the value chain into technology and innovation-driven sectors. Exor's willingness to back Philips through a difficult period—and now to increase its stake—signals confidence that the company can regain its footing and deliver returns that justify the risk.
No Conflicts, Just Steady Support
Publicly, the relationship between Exor and Philips has been devoid of the friction that often accompanies large shareholder stakes. There have been no reported conflicts or strategic divergences since the partnership began. Both parties have consistently emphasized alignment on long-term goals, mutual respect, and shared confidence in the transformation underway.
This harmony is somewhat unusual in an era when activist investors frequently clash with management over capital allocation, board composition, and strategic direction. The absence of such tensions suggests that Exor is content to play the role of patient capital provider, allowing Philips' management to execute its plan without the quarterly earnings pressures that can derail complex restructurings.
The Road Ahead
The updated accord leaves open the possibility of further increases in Exor's stake, subject to Philips Supervisory Board approval. Whether Exor will exercise that option depends on several factors: Philips' financial performance over the next two years, the broader health technology market's trajectory, and Exor's own capital allocation priorities across its diverse portfolio.
For now, the 22% cap provides Exor with room to maneuver without immediately triggering the governance complications that might arise from a larger position. It also sends a clear signal to other investors: the Agnelli family believes in Philips' recovery story and is willing to back that conviction with additional capital.
In a landscape where Italian corporate giants are increasingly looking beyond domestic borders for growth, the Exor-Philips partnership stands as a case study in how long-term strategic investment, patient capital, and boardroom influence can combine to reshape a troubled industrial icon—and potentially deliver substantial returns for those willing to wait.
